You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
HUTCHMED savolitinib NDA for MET-amplified gastric cancer accepted for priority review in China
Login
Username:

Password:


Related Headlines

Insilico Medicine signs multi-year research and development collaboration with Servier

MemorialCare hospitals recognised in 2026 Women's Choice Awards

International Isotopes Inc to change name to Radnostix Inc

Delcath publishes Phase 3 FOCUS subgroup data supporting HEPZATO in metastatic uveal melanoma

Corcept announces receipt of FDA Complete Response letter for relacorilant in hypercortisolism

Sensiva Health names new chief operating officer

HUTCHMED savolitinib NDA for MET-amplified gastric cancer accepted for priority review in China

SOFIE Biosciences reports first patient dosed Phase 3 clinical trial of [18F]FAPI-74

ABL Bio receives upfront payment and equity investment from Eli Lilly

Harbour BioMed and Yantai Lannacheng Biotechnology form collaboration to advance next-gen RDCs

Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m

Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance

AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer

Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer

BioNTech completes acquisition of CureVac

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026